Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK6 | Q16659 | 13/20 | 0.75 |
| ▸ | GSK3A | P49840 | 3/20 | 0.55 |
| ▸ | GSK3B | P49841 | 3/20 | 0.55 |
| ▸ | EIF2AK4 | Q9P2K8 | 3/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16014935 | 0.90 | MAPK6 (0.78) | MAPK6GSK3AGSK3BEIF2AK4PIM1 | |
| SCHEMBL16012215 | 0.88 | MAPK6 (0.90) | MAPK6GSK3AGSK3BEIF2AK4PIM1 | |
| SCHEMBL16012037 | 0.87 | MAPK6 (0.79) | MAPK6GSK3AGSK3BEIF2AK4PIM1 | |
| SCHEMBL16012149 | 0.87 | MAPK6 (0.79) | MAPK6GSK3AGSK3BEIF2AK4PIM1 | |
| SCHEMBL16012035 | 0.87 | MAPK6 (0.79) | MAPK6GSK3AGSK3BEIF2AK4PIM1 | |
| SCHEMBL16012150 | 0.87 | MAPK6 (0.79) | MAPK6GSK3AGSK3BEIF2AK4PIM1 | |
| SCHEMBL18830297 | 0.87 | MAPK6 (0.79) | MAPK6GSK3AGSK3BEIF2AK4PIM1 | |
| SCHEMBL16012036 | 0.87 | MAPK6 (0.79) | MAPK6GSK3AGSK3BEIF2AK4PIM1 | |
| SCHEMBL16022095 | 0.86 | MAPK6 (0.80) | MAPK6GSK3AGSK3BEIF2AK4PIM1 | |
| SCHEMBL16012108 | 0.85 | MAPK6 (1.00) | MAPK6GSK3AGSK3BEIF2AK4PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964649-B1 | TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2017-05-10 | — | — | EP | disclosed |